Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 2/20 | 0.35 |
| ▸ | CDC25B | P30305 | 2/20 | 0.35 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9730908 | 0.81 | — | — | |
| SCHEMBL5117712 | 0.80 | — | — | |
| SCHEMBL8941198 | 0.74 | PTPN1 (0.44) | PTPN1LMNAACP1CDC25BTSHR | |
| SCHEMBL10360973 | 0.71 | PTPN1 (0.43) | PTPN1ALDH1A1LMNAHSD17B10HTT | |
| SCHEMBL18957266 | 0.71 | — | — | |
| SCHEMBL21415445 | 0.70 | PTPN1 (0.43) | PTPN1CDC25B | |
| SCHEMBL21415459 | 0.70 | SMN1; SMN2 (0.36) | PTPN1ALDH1A1LMNAACP1CDC25B | |
| SCHEMBL21415456 | 0.69 | PIK3CD (0.32) | PTPN1 | |
| Ethylene SCHEMBL688288 | 0.69 | — | — | |
| SCHEMBL12511298 | 0.69 | SMN1; SMN2 (0.39) | PTPN1ALDH1A1LMNAHSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106496963-A | A kind of daily use chemicals packing box citicall limited aluminium film | 无锡三帝特种高分子材料有限公司 | 2017-03-15 | — | — | CN | claimed |
| US-12305082-B2 | Curable-type composition, two-component curable-type composition set, and method of producing adhered product | TOAGOSEI CO., LTD. | 2025-05-20 | — | — | US | disclosed |
| WO-2023002924-A1 | OPTICAL FILTER | ＡＧＣ株式会社 | 2023-01-26 | — | — | WO | disclosed |
| US-20230002642-A1 | CURABLE COMPOSITION, TWO-LIQUID TYPE CURABLE COMPOSITION SET, AND METHOD FOR MANUFACTURING ADHERED PRODUCT | TOAGOSEI CO., LTD. (JP) | 2023-01-05 | — | — | US | disclosed |
| US-20220380615-A1 | CURABLE COMPOSITION, TWO-LIQUID TYPE CURABLE COMPOSITION SET, AND METHOD FOR MANUFACTURING ADHERED PRODUCT | TOAGOSEI CO., LTD. (JP) | 2022-12-01 | — | — | US | disclosed |
| EP-3725815-B1 | ACTIVE ENERGY RAY-CURABLE COMPOSITION | UNIV TOKYO SCIENCE FOUND (JP) | 2022-10-05 | — | — | EP | disclosed |
| US-20220282135-A1 | CURABLE-TYPE COMPOSITION, TWO-COMPONENT CURABLE-TYPE COMPOSITION SET, AND METHOD OF PRODUCING ADHERED PRODUCT | TOAGOSEI CO., LTD. (JP) | 2022-09-08 | — | — | US | disclosed |
| CN-111465623-B | Active energy ray-curable composition | 学校法人东京理科大学 | 2022-08-02 | — | — | CN | disclosed |
| US-20220017474-A1 | Novel Polycyclic Compound | EUTEC NEW MATERIALS TECHNOLOGY (SUZHOU) CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-11180579-B2 | Active energy ray-curable composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2021-11-23 | — | — | US | disclosed |
| US-4935441-A | Flavene and thioflavene derivates, processes for their manufacture, pharmaceutical preparations that contain such compounds, and the use of the latter | ZYMA SA (CH) | 1990-06-19 | — | — | US | disclosed |
| US-4885298-A | Pharmaceutical preparations containing flavanone or thioflavanone derivatives the use thereof, novel flavanones and thioflavanones, and processes for their manufacture | ZYMA SA (CH) | 1989-12-05 | — | — | US | disclosed |
| EP-0140830-B1 | PHARMACEUTICAL PREPARATIONS CONTAINING FLAVENE OR THIOFLAVENE DERIVATIVES, THE USE THEREOF, NOVEL FLAVENES AND THIOFLAVENES, AND PROCESSES FOR THEIR MANUFACTURE | Zyma SA (CH) | 1989-08-30 | — | — | EP | disclosed |
| EP-0096007-B1 | PHARMACEUTICAL PREPARATIONS CONTAINING (+)-CYANIDAN-3-OL DERIVATIVES, THE USE THEREOF, NOVEL SUBSTITUTED (+)-CYANIDAN-3-OL DERIVATIVES, AND PROCESSES FOR PRODUCING THEM | Zyma SA (CH) | 1987-07-29 | — | — | EP | disclosed |
| US-4665202-A | Flavene and thioflavene derivatives | ZYMA SA (CH) | 1987-05-12 | — | — | US | disclosed |
| US-4644011-A | LIVER AND VIEN DISORDERS | ZYMA SA (CH) | 1987-02-17 | — | — | US | disclosed |
| EP-0140830-A2 | Pharmaceutical preparations containing flavene or thioflavene derivatives, the use thereof, novel flavenes and thioflavenes, and processes for their manufacture | Zyma SA (CH) | 1985-05-08 | — | — | EP | disclosed |
| EP-0139615-A2 | Flavene and thioflavene derivatives, processes for their manufacture, pharmaceutical preparations that contain such compounds, and the use of the latter | Zyma SA (CH) | 1985-05-02 | — | — | EP | disclosed |
| US-4510159-A | (+)-Cyanidan-3-ol derivatives, pharmaceutical preparations that contain such compounds, and the use of the latter to treat liver or venous diseases | ZYMA SA (CH) | 1985-04-09 | — | — | US | disclosed |
| EP-0096008-A2 | (+)-Cyanidan-3-ol derivatives, processes for their manufacture, pharmaceutical preparations that contain such compounds, and the use of the latter | Zyma SA (CH) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017474-A1 | Novel Polycyclic Compound | CUTA, DSG1, UACA | PTPN1 4563/4885ALDH1A1 1012/4885LMNA 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.